Lv3
280 积分 2025-07-01 加入
Management of Patients With Early-Stage Non-Small Cell Lung Cancer
2天前
已完结
The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross‐national comparison study
1个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
2个月前
已完结
Natural History of Stage I Non-Small Cell Lung Cancer
2个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
2个月前
已完结
Revisiting neoadjuvant therapy in non-small-cell lung cancer
2个月前
已完结
Treatment of Unfit Patients With Advanced Non–Small-Cell Lung Cancer: Definition Criteria According an Expert Panel
3个月前
已完结
Revisiting neoadjuvant therapy in non-small-cell lung cancer
3个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
Cancer statistics for the year 2020: An overview
4个月前
已完结
皖公网安备34019202002308
